Forging the Path to Precision Medicine in Qatar: A Public Health Perspective on Pharmacogenomics Initiatives
Author | Bastaki, Kholoud |
Author | Velayutham, Dinesh |
Author | Irfan, Areeba |
Author | Adnan, Mohd |
Author | Mohammed, Sawsan |
Author | Mbarek, Hamdi |
Author | Qoronfleh, Walid |
Author | Jithesh, Puthen Veettil |
Available date | 2024-03-24T05:29:38Z |
Publication Date | 2024-03-18 |
Publication Name | Frontiers in Public Health |
Identifier | http://dx.doi.org/10.3389/fpubh.2024.1364221 |
Citation | Bastaki K, Velayutham D, Irfan A, Adnan M, Mohammed S, Mbarek H, Qoronfleh MW and Jithesh PV (2024) Forging the path to precision medicine in Qatar: a public health perspective on pharmacogenomics initiatives. Front. Public Health. 12:1364221. doi: 10.3389/fpubh.2024.1364221 |
Abstract | Pharmacogenomics (PGx) is an important component of precision medicine that promises tailored treatment approaches based on an individual’s genetic information. Exploring the initiatives in research that help to integrate PGx test into clinical setting, identifying the potential barriers and challenges as well as planning the future directions, are all important for fruitful PGx implementation in any population. Qatar serves as an exemplar case study for the Middle East, having a small native population compared to a diverse immigrant population, advanced healthcare system, national genome program, and several educational initiatives on PGx and precision medicine. This paper attempts to outline the current state of PGx research and implementation in Qatar within the global context, emphasizing ongoing initiatives and educational efforts. The inclusion of PGx in university curricula and healthcare provider training, alongside precision medicine conferences, showcase Qatar’s commitment to advancing this field. However, challenges persist, including the requirement for population specific implementation strategies, complex genetic data interpretation, lack of standardization, and limited awareness. The review suggests policy development for future directions in continued research investment, conducting clinical trials for the feasibility of PGx implementation, ethical considerations, technological advancements, and global collaborations to overcome these barriers. |
Sponsor | The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Funding from the Qatar University and Hamad Bin Khalifa University are greatly acknowledged. The funders had no role in the study design, analysis or reporting. |
Language | en |
Publisher | Frontiers Media |
Subject | pharmacogenomics (PGx) population health precision health precision medicine Middle East Qatar |
Type | Article Review |
Volume Number | 12 |
ESSN | 2296-2565 |
Files in this item
This item appears in the following Collection(s)
-
Biomedical Sciences [738 items ]
-
Medicine Research [1508 items ]
-
Pharmacy Research [1311 items ]